Getinge AB (Getinge) is a medical device company that provides advanced technological solutions and expertise to hospitals and life science institutions. The company's main activities include offering solutions for intensive care, cardiovascular procedures, operating room, sterile reprocessing, digital health, pharmaceutical production, and research laboratories. Services include technical services, digital services, financial services, planning and design, project implementation, education and training, and hospital transformational partnerships. Getinge's solutions cater to intensive care, cardiovascular procedures, operating rooms, sterile reprocessing, digital health, pharmaceutical production, and research laboratories.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Getinge has undertaken several R&D initiatives focused on product development, digital strategy implementation, and successful product launches. It focuses on promoting innovation in sustainable practices and ensuring high product quality. It conducts research to improve its leadership offerings, enter new markets with low competition, and increase productivity while also meeting sustainability goals. The company is focused on broadening its portfolio to include innovative solutions in ECMO therapy and endovascular therapies. The company collaborates with top pharmaceutical companies and conducts research and development in various areas such as bioreactors, sterilizers, and disposable products. The company is currently focused on the strategy of innovation beyond 2030, which includes successful launches under its innovation and sustainability strategy and is continuously adding new projects, offering attractive digital solutions, which are an integral part and provide the company with competitive advantages, and has intensified its proactive M&A strategy to further strengthen innovativeness. Under the acute care therapies business area, the company focuses on product development and has implemented the digital strategy. In FY2024, it introduced Servo TwinView, which allows medical teams to analyze data from ventilators remotely, and Pulsiocare, which offers advanced hemodynamic monitoring with a high degree of user-friendliness. It also acquired Paragonix, which offers unique solutions for the safe transportation and storage of organs for transplantation. Under the life sciences business areas, the company focuses on AI development and introduced products such as the GEW 888 neo, which is a washer that consumes up to 32% less water depending on configuration, the Lancer LSS lab sterilize,r and a new version of the DPTE-BetaBag made from renewable plastics. It also acquired INTACT, an ecosystem of patents to create simpler and more cost-effective aseptic handling throughout the value chain. Under the surgical workflows business areas, the company introduced products such as the Maquet Ezea surgical light, the intuitive and high-performance Aquadis Index washer-disinfector, and the Poladus 150 low-temperature sterilizer. In FY2025, the company spent SEK1,452 million on its R&D activities, which as a percentage of revenue stood at 4.2%, and grew 1.5% YoY.